Yong-Chen Lu
Concepts (179)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Antigens, Neoplasm | 13 | 2022 | 170 | 4.480 |
Why?
| Receptors, Antigen, T-Cell | 10 | 2022 | 50 | 3.320 |
Why?
| Lymphocytes, Tumor-Infiltrating | 17 | 2022 | 74 | 3.220 |
Why?
| Immunotherapy, Adoptive | 8 | 2019 | 134 | 2.800 |
Why?
| T-Lymphocytes | 9 | 2022 | 373 | 2.610 |
Why?
| Neoplasms | 9 | 2022 | 1315 | 2.060 |
Why?
| Immunotherapy | 5 | 2021 | 263 | 1.800 |
Why?
| Cancer Vaccines | 4 | 2021 | 103 | 1.470 |
Why?
| High-Throughput Nucleotide Sequencing | 3 | 2021 | 206 | 1.310 |
Why?
| Mutation | 12 | 2019 | 1501 | 0.950 |
Why?
| CD4-Positive T-Lymphocytes | 4 | 2022 | 180 | 0.850 |
Why?
| Single-Cell Analysis | 3 | 2022 | 56 | 0.830 |
Why?
| Immune System | 1 | 2020 | 49 | 0.730 |
Why?
| Alcohol Oxidoreductases | 1 | 2019 | 14 | 0.700 |
Why?
| HLA-DP beta-Chains | 2 | 2017 | 2 | 0.660 |
Why?
| Neoplasm Proteins | 2 | 2017 | 359 | 0.620 |
Why?
| Genetic Therapy | 2 | 2017 | 121 | 0.610 |
Why?
| Urinary Bladder Neoplasms | 1 | 2019 | 173 | 0.610 |
Why?
| DNA-Binding Proteins | 1 | 2019 | 462 | 0.550 |
Why?
| Melanoma | 3 | 2016 | 313 | 0.550 |
Why?
| CD8-Positive T-Lymphocytes | 7 | 2022 | 116 | 0.530 |
Why?
| Proto-Oncogene Proteins p21(ras) | 4 | 2019 | 69 | 0.500 |
Why?
| Immunodominant Epitopes | 2 | 2015 | 12 | 0.500 |
Why?
| Protein Phosphatase 1 | 1 | 2013 | 6 | 0.470 |
Why?
| Phosphoprotein Phosphatases | 1 | 2013 | 20 | 0.460 |
Why?
| Cytokines | 4 | 2019 | 676 | 0.450 |
Why?
| Proto-Oncogene Proteins c-rel | 2 | 2010 | 5 | 0.450 |
Why?
| Lymphocyte Activation | 5 | 2021 | 197 | 0.450 |
Why?
| Humans | 29 | 2022 | 54246 | 0.400 |
Why?
| Antibodies, Monoclonal | 1 | 2016 | 562 | 0.400 |
Why?
| Colorectal Neoplasms | 3 | 2019 | 235 | 0.390 |
Why?
| Neoplasm Metastasis | 3 | 2022 | 252 | 0.380 |
Why?
| CCAAT-Enhancer-Binding Protein-beta | 1 | 2009 | 4 | 0.350 |
Why?
| Animals | 11 | 2022 | 14385 | 0.350 |
Why?
| Toll-Like Receptors | 1 | 2009 | 25 | 0.350 |
Why?
| Lipopolysaccharides | 2 | 2022 | 199 | 0.350 |
Why?
| CCAAT-Enhancer-Binding Protein-delta | 1 | 2009 | 25 | 0.340 |
Why?
| Transcriptome | 2 | 2022 | 346 | 0.340 |
Why?
| Glioblastoma | 2 | 2021 | 99 | 0.330 |
Why?
| Toll-Like Receptor 4 | 1 | 2008 | 51 | 0.310 |
Why?
| Signal Transduction | 5 | 2019 | 1753 | 0.300 |
Why?
| Adoptive Transfer | 3 | 2018 | 38 | 0.280 |
Why?
| Cells, Cultured | 5 | 2021 | 1737 | 0.270 |
Why?
| Gene Expression Profiling | 2 | 2021 | 1138 | 0.260 |
Why?
| Autoantigens | 2 | 2015 | 64 | 0.250 |
Why?
| T-Lymphocytes, Regulatory | 2 | 2016 | 85 | 0.240 |
Why?
| Gene Library | 2 | 2014 | 50 | 0.240 |
Why?
| Nephritis | 1 | 2022 | 27 | 0.210 |
Why?
| Receptors, Immunologic | 1 | 2022 | 37 | 0.210 |
Why?
| Clone Cells | 2 | 2019 | 89 | 0.210 |
Why?
| HLA-A Antigens | 2 | 2019 | 13 | 0.200 |
Why?
| Ureteral Obstruction | 1 | 2022 | 70 | 0.200 |
Why?
| Human papillomavirus 16 | 1 | 2021 | 48 | 0.200 |
Why?
| Adaptor Proteins, Signal Transducing | 2 | 2014 | 208 | 0.200 |
Why?
| Tumor Suppressor Protein p53 | 2 | 2022 | 250 | 0.200 |
Why?
| T-Cell Antigen Receptor Specificity | 2 | 2017 | 5 | 0.190 |
Why?
| Membrane Glycoproteins | 1 | 2022 | 269 | 0.190 |
Why?
| Papillomavirus Vaccines | 1 | 2021 | 67 | 0.190 |
Why?
| Middle Aged | 8 | 2019 | 13070 | 0.180 |
Why?
| Interleukin-2 | 2 | 2017 | 75 | 0.180 |
Why?
| Smad5 Protein | 1 | 2019 | 1 | 0.170 |
Why?
| Mucin-4 | 1 | 2019 | 1 | 0.170 |
Why?
| Renal Insufficiency, Chronic | 1 | 2022 | 182 | 0.170 |
Why?
| Uterine Cervical Neoplasms | 1 | 2021 | 276 | 0.170 |
Why?
| Cell Differentiation | 1 | 2021 | 720 | 0.160 |
Why?
| Administration, Intravenous | 1 | 2017 | 75 | 0.150 |
Why?
| Epitopes, T-Lymphocyte | 2 | 2014 | 33 | 0.150 |
Why?
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 573 | 0.150 |
Why?
| Colonic Neoplasms | 1 | 2019 | 164 | 0.150 |
Why?
| Membrane Proteins | 1 | 2019 | 389 | 0.150 |
Why?
| Exome | 2 | 2014 | 51 | 0.150 |
Why?
| Flow Cytometry | 3 | 2016 | 546 | 0.140 |
Why?
| CTLA-4 Antigen | 1 | 2016 | 29 | 0.140 |
Why?
| T-Lymphocytes, Helper-Inducer | 1 | 2016 | 46 | 0.140 |
Why?
| Programmed Cell Death 1 Receptor | 1 | 2016 | 40 | 0.140 |
Why?
| Cell Line, Tumor | 2 | 2017 | 1550 | 0.140 |
Why?
| Transplantation, Autologous | 1 | 2017 | 476 | 0.140 |
Why?
| Gene Expression Regulation | 2 | 2019 | 1062 | 0.130 |
Why?
| Transcription Factors | 1 | 2019 | 622 | 0.130 |
Why?
| Protein Binding | 2 | 2014 | 736 | 0.130 |
Why?
| Gastrointestinal Neoplasms | 1 | 2015 | 46 | 0.130 |
Why?
| Neutrophils | 2 | 2014 | 154 | 0.130 |
Why?
| Male | 6 | 2019 | 27312 | 0.130 |
Why?
| Adult | 7 | 2021 | 14182 | 0.130 |
Why?
| Hepatitis B e Antigens | 1 | 2014 | 2 | 0.130 |
Why?
| Respiratory Burst | 1 | 2014 | 4 | 0.130 |
Why?
| Histocompatibility Antigens | 1 | 2014 | 6 | 0.130 |
Why?
| Epitope Mapping | 1 | 2014 | 12 | 0.130 |
Why?
| Chemotaxis, Leukocyte | 1 | 2014 | 20 | 0.130 |
Why?
| Treatment Outcome | 4 | 2021 | 5604 | 0.130 |
Why?
| Bile Ducts, Intrahepatic | 1 | 2014 | 17 | 0.120 |
Why?
| Time Factors | 2 | 2021 | 3212 | 0.120 |
Why?
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 866 | 0.120 |
Why?
| Aged | 2 | 2019 | 10041 | 0.120 |
Why?
| Cholangiocarcinoma | 1 | 2014 | 30 | 0.120 |
Why?
| Bile Duct Neoplasms | 1 | 2014 | 33 | 0.120 |
Why?
| Th1 Cells | 1 | 2014 | 50 | 0.120 |
Why?
| Monocytes | 1 | 2014 | 156 | 0.120 |
Why?
| Alleles | 1 | 2014 | 277 | 0.120 |
Why?
| Female | 10 | 2021 | 28418 | 0.110 |
Why?
| Gene Knockdown Techniques | 1 | 2013 | 125 | 0.110 |
Why?
| Peptides | 1 | 2014 | 276 | 0.110 |
Why?
| Amino Acid Sequence | 1 | 2014 | 767 | 0.110 |
Why?
| NF-kappa B | 2 | 2011 | 335 | 0.110 |
Why?
| Genes, T-Cell Receptor | 2 | 2022 | 5 | 0.110 |
Why?
| TNF Receptor-Associated Factor 2 | 1 | 2011 | 4 | 0.110 |
Why?
| Base Sequence | 1 | 2013 | 719 | 0.100 |
Why?
| Autoimmunity | 1 | 2011 | 38 | 0.100 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 673 | 0.100 |
Why?
| Forkhead Transcription Factors | 1 | 2012 | 118 | 0.100 |
Why?
| Molecular Sequence Data | 1 | 2013 | 980 | 0.100 |
Why?
| Disease Progression | 1 | 2014 | 913 | 0.100 |
Why?
| Cell Line | 1 | 2014 | 1153 | 0.100 |
Why?
| Lung Neoplasms | 1 | 2016 | 642 | 0.090 |
Why?
| Clinical Trials as Topic | 1 | 2013 | 490 | 0.090 |
Why?
| Clonal Anergy | 1 | 2010 | 14 | 0.090 |
Why?
| Protein Kinase C | 1 | 2010 | 65 | 0.090 |
Why?
| Dendritic Cells | 2 | 2022 | 142 | 0.090 |
Why?
| Remission Induction | 2 | 2021 | 221 | 0.090 |
Why?
| Interleukin-1 Receptor-Associated Kinases | 1 | 2009 | 11 | 0.090 |
Why?
| Isoenzymes | 1 | 2010 | 177 | 0.090 |
Why?
| Myeloid Differentiation Factor 88 | 1 | 2009 | 40 | 0.090 |
Why?
| Mice | 4 | 2022 | 6413 | 0.090 |
Why?
| Transcriptional Activation | 1 | 2009 | 134 | 0.080 |
Why?
| Breast Neoplasms | 1 | 2018 | 1248 | 0.080 |
Why?
| Inflammation Mediators | 1 | 2009 | 128 | 0.080 |
Why?
| Antineoplastic Agents | 1 | 2017 | 1300 | 0.080 |
Why?
| Antigen Presentation | 2 | 2019 | 28 | 0.080 |
Why?
| Complement C3a | 1 | 2007 | 3 | 0.080 |
Why?
| Complement C5a | 1 | 2007 | 4 | 0.080 |
Why?
| Cell Separation | 2 | 2019 | 107 | 0.080 |
Why?
| Macrophages | 1 | 2009 | 405 | 0.070 |
Why?
| Lymphocyte Count | 2 | 2016 | 23 | 0.060 |
Why?
| Th17 Cells | 1 | 2022 | 26 | 0.050 |
Why?
| Clinical Trials, Phase I as Topic | 1 | 2021 | 30 | 0.050 |
Why?
| Neoplasm Grading | 1 | 2021 | 131 | 0.050 |
Why?
| Gene Regulatory Networks | 1 | 2022 | 124 | 0.050 |
Why?
| Arginine | 1 | 2022 | 182 | 0.050 |
Why?
| Host-Pathogen Interactions | 1 | 2021 | 143 | 0.050 |
Why?
| Nitric Oxide | 1 | 2022 | 298 | 0.050 |
Why?
| Blotting, Western | 2 | 2011 | 683 | 0.040 |
Why?
| Transduction, Genetic | 1 | 2019 | 50 | 0.040 |
Why?
| Lung | 2 | 2016 | 507 | 0.040 |
Why?
| Immunologic Memory | 1 | 2019 | 32 | 0.040 |
Why?
| Transplantation Conditioning | 1 | 2019 | 86 | 0.040 |
Why?
| Coculture Techniques | 1 | 2019 | 160 | 0.040 |
Why?
| Molecular Targeted Therapy | 1 | 2019 | 128 | 0.040 |
Why?
| Neoplastic Cells, Circulating | 1 | 2019 | 93 | 0.040 |
Why?
| Phenotype | 2 | 2012 | 820 | 0.040 |
Why?
| Lymphatic Metastasis | 1 | 2019 | 256 | 0.040 |
Why?
| HLA-DRB1 Chains | 1 | 2017 | 8 | 0.040 |
Why?
| Proteasome Endopeptidase Complex | 1 | 2018 | 131 | 0.040 |
Why?
| Antigen-Presenting Cells | 1 | 2017 | 25 | 0.040 |
Why?
| Cell Proliferation | 1 | 2021 | 1096 | 0.040 |
Why?
| Cross Reactions | 1 | 2016 | 56 | 0.040 |
Why?
| Pilot Projects | 1 | 2019 | 808 | 0.040 |
Why?
| HLA-C Antigens | 1 | 2015 | 4 | 0.030 |
Why?
| ras Proteins | 1 | 2015 | 70 | 0.030 |
Why?
| Proto-Oncogene Proteins | 1 | 2015 | 169 | 0.030 |
Why?
| Inflammation | 2 | 2011 | 674 | 0.030 |
Why?
| Clinical Trials, Phase II as Topic | 1 | 2014 | 51 | 0.030 |
Why?
| Chemokines | 1 | 2014 | 96 | 0.030 |
Why?
| Vaccination | 1 | 2016 | 293 | 0.030 |
Why?
| Receptor, erbB-2 | 1 | 2014 | 79 | 0.030 |
Why?
| B-Lymphocytes | 1 | 2014 | 176 | 0.030 |
Why?
| Recombinant Proteins | 1 | 2014 | 569 | 0.030 |
Why?
| Dose-Response Relationship, Immunologic | 1 | 2012 | 16 | 0.030 |
Why?
| Whole-Body Irradiation | 1 | 2012 | 160 | 0.020 |
Why?
| Polymerase Chain Reaction | 1 | 2011 | 531 | 0.020 |
Why?
| Mice, Knockout | 1 | 2011 | 926 | 0.020 |
Why?
| Apoptosis | 1 | 2014 | 1300 | 0.020 |
Why?
| Mice, Transgenic | 1 | 2010 | 656 | 0.020 |
Why?
| Receptor, Anaphylatoxin C5a | 1 | 2007 | 5 | 0.020 |
Why?
| Receptors, Chemokine | 1 | 2007 | 13 | 0.020 |
Why?
| Complement Activation | 1 | 2007 | 43 | 0.020 |
Why?
| Cattle | 1 | 2007 | 224 | 0.020 |
Why?
| Actins | 1 | 2007 | 132 | 0.020 |
Why?
| Hematopoietic Stem Cells | 1 | 2007 | 215 | 0.020 |
Why?
| Fibroblasts | 1 | 2007 | 386 | 0.020 |
Why?
|
|
Lu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|